

Bidders for the 2026 World Congress of Basic and Clinical Pharmacology (WCP2026)

IUPHAR thanks the 9 member societies that volunteered to host WCP2026. Following an initial judging by the IUPHAR Voting Delegates, the below 4 finalists will present their bids during the General Assembly on Wednesday, July 4th in room B1 of the Kyoto International Conference Center during WCP2018, where the Voting Delegates will cast their ballots to determine the winner. WCP2018 registrants are invited as observers. Doors open at 6 p.m.

**Budapest,
Hungary
19-24 July, 2026**



**Melbourne,
Australia
13-18 July, 2026**



**Montreal,
Canada
11-18 July, 2026**



**Prague, Czech
Republic
8-12 July, 2026**

Nominees to the 2018 - 2022 IUPHAR Executive Committee

The Nominating Committee, consisting of Kim Brøsen (Denmark), John Miners (Australia), Kathy Giacomini (USA), Mohamed Khayyal (Egypt), Zhi-Bin Lin (China) and Carlo Riccardi (Italy), is pleased to introduce the individuals nominated to the 2018 - 2022 IUPHAR Executive Committee. Their brief biosketches are on the following pages. The elections are scheduled as part of the IUPHAR General Assembly on Wednesday, July 4th in room B1 of the Kyoto International Conference Center. WCP2018 registrants are invited as observers. Doors open at 6 p.m.

For President



Ingolf Cascorbi,
Germany

For 1st Vice President



Francesca Levi-
Schaffer, Israel

For 2nd Vice President



Yoshikatsu Kanai,
Japan

For Secretary General



Michael Spedding,
France

For Treasurer



James E. Barrett,
USA

For Councilor (5 positions)



Arthur
Christopoulos,
Australia



Guan-Hua Du,
China



Helen Ochuko
Kwanashie, Nigeria



Guilherme Suarez-
Kurtz, Brazil



David J. Webb,
United Kingdom

Continued on page 18...



Ingolf Cascorbi, MD, PhD Nominated for President

Ingolf Cascorbi (Germany) received a diploma degree (Biochemistry, 1985) and a Ph.D. (Biochemistry, 1989) from the Free University, Berlin, Germany. Additionally he graduated at the same university in medicine (1992). He continued his scientific career as research associate at the Institute of Clinical Pharmacology, Charité, Humboldt University Berlin, where he worked under the supervision of Ivar Roots. In 1998 Dr. Cascorbi specialized in clinical pharmacology, received a Dr. med. (M.D.) in 1999 and achieved his habilitation in clinical pharmacology in 2000. In the same year he became Associate Professor of Pharmacology and Toxicology at the University of Greifswald. In 2004 he was appointed as Full Professor of Pharmacology, Christian Albrechts University Kiel and Director of the Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein (UKSH), Campus Kiel, Germany.

Dr. Cascorbi has held many elected and appointed offices. For six years he served on the Academic Senate of the University of Kiel. Since 2012 he is Dean of Education of the Medical Faculty. He is Vice Chair of the UKSH Committee for Medicinal Products, Vice Chair of the Ethics Committee and Chief Advisor of the Center of Clinical Studies.

Outside the university he was appointed as Member of the Health Care Professional Working Party European Medicines Agency (EMA) and the Scientific Advisory Board of the German Agency of Drugs and Medical Devices (BfArM). Currently he is Member of the Gene Diagnostics Commission, German Ministry of Health and the Drug Commission of the German Medical Association.

From 2003-2015 Dr. Cascorbi served on the executive Board of the European Association for Clinical Pharmacology and Therapeutics (EACPT), from 2007-2011 as its chairperson. From 2006-2014 he was elected as Chair of the IUPHAR Section of Pharmacogenetics and Pharmacogenomics. Additionally Ingolf Cascorbi is Vice Chair of the German Society for Clinical Pharmacology and Therapy and executive board member of the European Society for Pharmacogenomics and Personalized Therapy (ESPT).

Ingolf Cascorbi is member of several editorial boards: Basic and Clinical Pharmacology and Toxicology, British Journal of Clinical Pharmacology, Clinical Pharmacology and Therapeutics (Associate Editor), Deutsches Ärzteblatt Intl., European Journal of Clinical Pharmacology, Pharmacogenetics and Genomics, Pharmacogenomics, Therapeutic Drug Monitoring.

He is member of the American Association for Cancer Research (AACR), American Society for Clinical Pharmacology and Therapeutics (ASCPT), Association for Applied Human Pharmacology (AGAH), British Society for Pharmacology (BPS), European Society for Pharmacogenomics and Personalized Therapy (ESPT), German Interdisciplinary Association for Intensive Care and Emergency Medicine (DIVI), German Society for Cardiology (DGK), German Society for Clinical Pharmacology and Therapeutics (DGKliPha).

His research interests are focused on pharmacogenomics and -epigenomics of drug metabolizing enzymes and membrane transporters, drug resistance in oncology, genetic risk factors of complex diseases, neurologic pain research and epilepsy. He has published more than 250 research reports, reviews, and book chapters.

Francesca Levi-Schaffer, PharmD, PhD Nominated for 1st Vice President

Francesca Levi-Schaffer (Israel) is a Professor at the Hebrew University of Jerusalem (HUJI) in the Institute for Drug Research of the School of Pharmacy, Faculty of Medicine. She holds the Isaac and Myrna Kaye Chair in Immunopharmacology. From 2006-2009 Prof. Levi-Schaffer was Chair of the Department of Pharmacology and Experimental Therapeutics and head of the Teaching Unit of Pharmacology and Experimental Therapeutics in the HUJI Faculty of Medicine, School of Pharmacy. Prof. Levi-Schaffer was born in Italy and completed her PharmD degree at the University of Milano. In 1984 she received her PhD degree in Immunology from the Weizmann Institute, Rehovot, Israel. Her post-doctoral training was at Harvard Medical School (1984-86).

Continued on page 19...

Francesca Levi-Schaffer, PharmD, PhD Nominated for 1st Vice President (continued)

Prof. Levi-Schaffer has published 160 articles in peer-reviewed journals, 83 reviews and editorials and 25 book chapters. She has one patent and two provisional patents pending. In 2011 she was elected Chairperson of the National Committee of the International Union of Basic and Clinical Pharmacology (IUPHAR) representing the Israel Academy of Sciences and Humanities. In 2012, she was instrumental in the establishment of an Immunopharmacology Section in the IUPHAR and serves as its first Chairperson. She is a member of the Israeli Ministry of Health Committee for Human Experimentation of New Drugs, a Councilor and member of the Executive Committee of the International Union of Basic and Clinical Pharmacology (IUPHAR); Treasurer (2016-18), Secretary General (2018-20) and member of the Board of Directors of the World Allergy Organization; a Council member of the Collegium Internationale Allergologicum (CIA); a member of the Immunopharmacology Task Force and the AllergoOncology Task Force of the European Academy of Allergy and Clinical Immunology (EAACI).

Prof. Levi-Schaffer's expertise is in the area of immunopharmacology of allergy focusing on mast cells and eosinophils, their activating and inhibitory receptors, their cross-talk for a better prophylaxis/treatment of allergic diseases. Moreover, she is studying the role of mast cells and eosinophils in hypoxia (allergy, COPD); mastocytosis and its treatment; the crosstalk between atopic dermatitis and asthma with the microbiome; and she is developing novel monoclonal antibodies and bispecific antibodies against activating and inhibiting receptors on mast cells and eosinophils for the treatment of allergy and of selected solid tumors.

Yoshikatsu Kanai, MD, PhD Nominated for 2nd Vice President

Yoshikatsu Kanai (Japan) received his M.D. degree from Gunma University (Japan) in 1984 and Ph.D. (Medicine) from The University of Tokyo (Japan) in 1988. He completed his postdoctoral training at The University of Tokyo (Toxicology, 1988–1991) and at Brigham and Women's Hospital, Harvard University in US (Nephrology and Molecular Pharmacology, 1991–1993). Appointed to a faculty position as assistant professor of pharmacology at Kyorin University School of Medicine (Japan) in 1993, he was promoted to associate professor in 1996, and to professor of pharmacology in 2001. Since 2007, he has been full Professor of Pharmacology at Osaka University Graduate School of Medicine (Japan), where he is Chief of Department of Bio-system Pharmacology.

Dr. Kanai has been a member of the Japanese Pharmacological Society (JPS) since 1992. He joined the Scientific Council in 2002. He is currently a member of the Board of Directors of the Japanese Pharmacological Society, and also a member of ASPET. He has also been a core member of NC-IUPHAR since 2012. He has been serving as editorial board member of both *Biochemical Pharmacology* (2012–) and *Channels* (2007–). He received the JPS Setsuro Ebashi Award in 2014 for his research on the molecular pharmacology of transporters, their molecular identification and application to drug discovery.

Dr. Kanai's research interests center on the molecular pharmacology of transporters from both pharmacodynamic and pharmacokinetic point of view. He has identified and characterized more than 30 transporter molecules for organic solutes including nutrients and drugs, and searched for their possible applications as therapeutic targets. The transporters he identified include glucose transporter SGLT2 whose inhibitors have been clinically developed as anti-diabetic drugs, urate transporter URAT1 as a target of uricosuric drugs, organic anion transporters OATs some of which are critical for ADME and adopted in FDA guidance, and various amino acid transporters involved in neurotransmitter clearance, epithelial transport of amino acids and cellular nutrition. He has proposed the idea of "transportsome", the multi-molecular assembly involving transporters and the physically- and functionally-coupled membranous and/or extra-membranous components as a functional unit of transmembrane transport. He is now extending the scope of his research to the discovery of anti-tumor drugs and diagnostic agents targeting amino acid transporters in cancer cells as well as to the understanding of cellular signaling mediated by amino acid transporters.

Michael Spedding, PhD, FBPhS Nominated for 2018-2022 Secretary General

Michael Spedding (France) graduated with a BSc. Hons Pharmacy from Sunderland Polytechnic School of Pharmacy in 1971. He completed his preregistration pharmacist's requirements to obtain an MRPharmS from Sunderland General Hospital before completing his PhD under the direction of D.F. Weetman and A.J. Sweetman of Sunderland Polytechnic and R.T. Brittain of Glaxo, where he differentiated adenosine and ATP receptors.

After spending four years as a lecturer in pharmacy/pharmacology for Sunderland Polytechnic, Dr. Spedding joined Merrell Dow Research Institute in Strasbourg in 1978 where he became the project leader for cardiovascular

Michael Spedding, PhD, FBPhS Nominated for Secretary General (continued)

drugs, assisting in the discovery of D,L- α -difluoromethylornithine (DFMO) and earned an international reputation on calcium channels, defining allosteric mechanisms of drugs at channels, multiple different drug binding sites and the first effects of calcium channel modulators in the brain. In 1985, he was appointed the pharmacology director and therapeutic area director for Preclinical and Clinical Central Nervous System (CNS) Drugs in the Edinburgh labs of Syntex – the group progressed drugs for stroke, angina and sexual dysfunction into late clinical development.

Dr. Spedding then joined the Institute de Recherche Servier in Paris in 1992 where he advanced from research center director to scientific director in 2004. During his tenure, he served as the scientific liaison director for Egis Pharmaceuticals, PLC in Budapest and set up key enabling experiments on new drugs and disease targets. He built two research centres for Servier. He has been associated with the passage of 11 drugs into clinical trials. After twenty two years with Servier, Dr. Spedding launched a research company, Spedding Research Solutions, where he specializes in new approaches in psychiatry, neuroinflammation and amyotrophic lateral sclerosis. Dr. Spedding's research has been published in over 190 full scientific papers with an h-index of 56 and he has initiated more than 20 patents. In his spare time he has cumulated several decades of athletic competition and a scientific interest in human performance and ageing.

Dr. Spedding has been elected to the French Academy of Pharmacy and as a fellow of the BPS. In addition, he has a long history with IUPHAR, where he has served on the Nomenclature Committee (NC-IUPHAR) as secretary for a decade before being appointed as the chair in 2002. He was elected Secretary General of IUPHAR in 2014 where he has focused his energy on academic drug discovery, synergizing natural products and New Chemical Entities, and expanding the online resources of IUPHAR.



James E. Barrett, PhD Nominated for Treasurer

Dr. James E. Barrett (USA) is a Professor in the Department of Neurology, Pharmacology and Physiology and former Chair of the Department of Pharmacology and Physiology, Drexel University College of Medicine. He received his Ph.D. from Pennsylvania State University followed by postdoctoral training in neuropsychopharmacology at the Worcester Foundation for Experimental Biology. During his 7 years as Chair at Drexel, he was the Founding Director of the Drug Discovery and Development Program, and of the Clinical and Translational Research Institute of Drexel University. He has served on the faculty at the University of Maryland and the Uniformed Services University of the Health Sciences where he was Professor in the Departments of Psychiatry, Pharmacology and Medical Psychology. Dr. Barrett joined Wyeth as Vice President of Neuroscience Discovery Research following the merger with Lederle Laboratories where he had been Director of Central Nervous System Research. Prior to his return to academia at Drexel University College of Medicine, he was Senior Vice President, Chief Scientific Officer, and President of Research at Adolor Corporation, a company focused on pain pharmaceuticals. He moved to Adolor after serving as President of Research and Development at Memory Pharmaceuticals, a biopharmaceutical company founded by the Nobel Laureate Eric Kandel, dedicated to the development of drugs for the treatment of central nervous system (CNS) disorders.

He has published more than 300 scientific articles, books and abstracts in the areas of substance abuse, neuropharmacology, neurobiology, behavioral pharmacology, translational research and neuroscience and serves on several editorial boards. He was President of the Behavioral Pharmacology Society and of the American Society for Pharmacology and Experimental Therapeutics (ASPET). He also served as the Chair of the Board of Publication Trustees for ASPET and was on the Board of Directors for the Federation

James E. Barrett, PhD Nominated for Treasurer (continued)

of American Societies for Experimental Biology (FASEB), where he was a member of the Science Policy Committee and the Public Affairs Committee as well as Chair of the “Breakthrough Series in Science” and “Horizons in Bioscience” Series. Dr. Barrett was recently appointed Editor-in-Chief of the Handbook of Experimental Pharmacology, one of the most authoritative and influential series in pharmacology, with an 80-year history of contributions to the discipline.

He has received the Solvay-Duphar Award for Research on Affective Disorders, the George B. Koelle Award from the Mid-Atlantic Pharmacology Society for contributions to teaching and research and the P.B. Dews Lifetime Achievement Award for Research in Behavioral Pharmacology. He is also the recipient of the Torald Sollmann Award in Pharmacology for significant contributions to the advancement and extension of knowledge in the field of pharmacology. Dr. Barrett served as a member of the External Scientific Advisory Board (SAB), Preclinical Autism Consortium for Therapeutics and has served on the SABs of Biogen-Idec, Cephalon and Eli Lilly. He recently joined the SAB of Yumanity Therapeutics. He has served as the President of the Association of Medical School Pharmacology Chairs and Councilor, International Union of Basic and Clinical Pharmacology (IUPHAR). In addition to being a member of ASPET, he is also a member of AAAS, the American Pain Society and is a Fellow of the American College of Neuropsychopharmacology. His current research emphasis is on pain, its co-morbid pathologies, basic mechanisms and biomarkers, and on the development of new therapeutics for pain disorders emerging from academic research.

Arthur Christopoulos, PhD Nominated for Councilor

Arthur Christopoulos (Australia) is the Professor of Analytical Pharmacology and Head of the Drug Discovery Biology Theme in the Monash Institute of Pharmaceutical Sciences, Monash University, Australia. He is also a Senior Principal Research Fellow of the National Health and Medical Research Council of Australia. He obtained his Bachelor of Pharmacy and PhD in Pharmacology from the Victorian College of Pharmacy, Monash University, followed by postdoctoral studies at the University of Minnesota.

His research focuses on novel paradigms of drug action at G protein-coupled receptors (GPCRs), the largest class of drug targets, and incorporate computational and mathematical modeling, analytical and molecular pharmacology, medicinal chemistry, structural and chemical biology, and animal models of disease. In particular, Dr. Christopoulos is a leading authority in the study of allosteric modulation and biased agonism at GPCRs. He has developed assays and analytical procedures that facilitate the detection, validation and quantification of allosteric drug effects, made key contributions to the discovery of first-in-class allosteric or biased ligands for muscarinic, cannabinoid, adenosine and opioid receptors, and pioneered a new mode of selective drug action involving hybrid (“bitopic”) molecules that concomitantly bridge both orthosteric and allosteric binding sites on a single receptor. More recently, he has extended his studies towards understanding the structural basis of allosteric drug binding and modulation, as well as exploring the potential of allosteric and biased molecules to target cognitive deficits, cardiovascular disorders and neuropathic pain.

Dr. Christopoulos has over 280 publications, over 165 invited presentations, has served on the Editorial Board of 8 journals, including Mol. Pharm., J.P.E.T., Pharm. Rev., B.J.P. and ACS Chem. Neurosci., and consults for numerous companies. He has had a long-standing relationship with IUPHAR, initially as a Corresponding Member of NC-IUPHAR and Chair of the NC-IUPHAR muscarinic receptor nomenclature committee, and now as NC-IUPHAR Deputy Chair. He led the recent NC-IUPHAR initiative that culminated in the development of the first uniform nomenclature for describing allostery across all receptor superfamilies (GPCRs, ion channels, nuclear receptors and receptor tyrosine kinases). Dr. Christopoulos has also made long-standing contributions to the discipline through his roles in other IUPHAR member Societies, including former Councilor of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the International Society for Serotonin Research.

His contributions to the field have been recognized through receipt of the John J. Abel Award from the American Society of Pharmacology and Experimental Therapeutics, the ASCEPT Rand Medal, the Distinguished Lecturer Award from the American College of Neuropsychopharmacology, the British Pharmacological Society’s Gaddum Memorial Award, the IUPHAR Analytical Pharmacology Lecturer and a Doctor of Laws (Honoris Causa) from the University of Athens. Since 2014, Thomson Reuters/Clarivate Analytics have annually named him a Highly Cited Researcher in Pharmacology and Toxicology. In 2017, he was elected a Fellow of the Australian Academy of Health and Medical Sciences.



Guan-Hua Du, PhD Nominated for Councilor

Guan-Hua Du (China) received his B.S. degree in Pharmacy from Shandong University (China) in 1982 and M. S. degree in Medicine from Tongji Medical University (China) in 1989. He obtained his Ph.D. degree in Pharmacology from Peking Union Medical College (China) in 1995. He did postdoctoral research at the University of Liege (Belgium) from 1995-1998. After returning to China, Dr. Du worked as professor at Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College as the Director of National Centre for Pharmaceutical Screening in 1998. Dr. Du is now professor of pharmacology at the Institute of Materia Medica in the Chinese Academy of Medical Science and Peking Union Medical College. He is the director of the National Center for Pharmaceutical Screening.

Dr. Du established the China's first high-throughput drug screening system, which was approved by the National Ministry of Science and Technology. By using a network-style screening strategy and the neurovascular unit integration target theory, he developed Pinocembrin as a novel drug against cerebral ischemia. Dr. Du also developed another novel drug named Baicalein used for treatment of Parkinson's disease, which was designed to adjust the balance of central neurotransmitters. These two drugs have now entered phase II clinical trials in China, respectively. He also took the lead in promoting the development of crystalline drug research in China and had finished the preclinical research of a new (polymorphs) drug Nitrendipine. Dr. Du also developed "injection of salvianolic acids" as a drug against cerebral ischemia for clinical use.

He was awarded the first and second prizes of the Beijing Science and Technology Awards for Technological Innovation in 2002 and 2009; Third prize of Chinese medical science and technology Awards for Technological Innovation in 2002 and 2011; National Outstanding Scientific and Technological Workers Award in 2010; Outstanding teachers Award in Beijing in 2011; Second prize of Chinese Ministry of Education outstanding achievements in scientific research of Higher School Award in 2012; Third prize of Chinese Pharmaceutical Association Award for Technological Innovation in 2014.; Second prize of National Scientific and Technological Progress award in 2016.

Dr. Du has published more than 700 peer review papers and edited 40 books in the area of pharmacology. In addition, he has obtained more than 60 patents (China and PCT). He has been invited to more than 200 times as speaker domestic and international conferences. His research interest focus on the drug discovery, includes the development and application of high throughput screening theory and strategy, neuropharmacology, cardiovascular pharmacology and the modernization of traditional Chinese Medicine. He is also editorial board member of more than 10 journals.

Dr. Du was the president of the CNPHARS from 2007 until 2017. He focuses on the advancement of academic communication and cooperation between domestic and foreign pharmacology societies, through the convening of conferences, seminars and workshops to promote contact between Chinese scholars and scholars from various countries. He is also a councilor of the Executive Committee of Asian Pacific Federation of Pharmacologists.

Helen Ochuko Kwanashie, PhD Nominated for Councilor

Helen O. Kwanashie (Nigeria) obtained her BSc and MSc Biochemistry degrees from University of Ibadan, and PhD Pharmacology from Ahmadu Bello University (ABU), in 1979, 1981 and 1991 respectively. Her postdoctoral training was at Dept of Biochemical Medicine, University of Dundee in Scotland. As a career academic, Prof Kwanashie has been teaching and researching at ABU for 35 years: from 1982 when she was appointed assistant lecturer

Helen Ochuko Kwanashie, PhD Nominated for 2018-2022 Councilor (continued)

teaching biochemistry in the first few years, through 1991 when she was staff-in-training working on her PhD, and rising through the ranks to full professor of pharmacology in 2004. She has taught pharmacology to undergraduate and postgraduate pharmacy, medical, nursing, veterinary and biomedical sciences students in Nigeria (at ABU and some other universities as visiting adjunct or sabbatical professor), as well as abroad (as visiting professor to University of Sierra Leone).

As one who routinely mainstreams women and children issues into her teaching, research and community service, Prof Kwanashie logically has her principal area of professional/research interest to be perinatal-cum-paediatric pharmacology, with interfacing interests in disease conditions that are prevalent in the tropics and developing world - such as malaria, HIV/AIDS and sickle cell disorder. Her secondary research thrust is pharmacology education. She has supervised several research-based BPharm projects, MSc theses and PhD dissertations; and recently established the Helen Ochuko Kwanashie Research Alumni and Students (HOKRAS) - an innovative group to facilitate mostly peer-based guidance-cum-support to her current and former postgraduate students. Prof Kwanashie's publications include 73 peer-reviewed journal articles, 22 journal-published conference abstracts, 4 book chapters, 8 project reports, 1 pharmacology-based art exhibition, etc. In addition, she has been a manuscript reviewer for many reputable journals and for over a decade, was on the editorial board of the West African Journal of Pharmacology and Drug Research.

Prof Kwanashie is on the 2014-2018 executive committee of IUPHAR Education Section and was president of West African Society for Pharmacology (WASP) from 2008 to 2013, facilitated monumental advances including re-integration of non-Nigerian participation after 29-years absence. As an active member of some other pharmacological societies/groups e.g. Pharmacology for Africa Initiative (PharfA), British Pharmacological Society (BPS) and American Society for Pharmacology and Experimental Therapeutics (ASPET), Prof Kwanashie has harnessed her experiences to advance the careers of her peers, junior colleagues as well as her own, in and outside the discipline.

Prof Kwanashie is recipient of many scholarships, fellowships and other awards from universities, professional societies, pharmaceutical companies and government; including 1993 Postdoctoral Research Award from Wellcome Trust (UK), 2014 Teaching Excellence Award from IUPHAR_Ed and 2017 Pharmacology Educator Award from ASPET_DPE. In her home university, she has severally been named 'Outstanding lecturer' and 'Best lecturer in Pharmacology' by student bodies.

Prof Kwanashie has been actively engaged in pharmacology education research, culminating in many result-oriented publications spanning over two decades. She believes that pharmacology education has evolved sufficiently to be ascribed the status of a full-fledged sub-discipline, and is advocating for development of postgraduate certificate, diploma and master programmes in pharmacology education, akin to what exists for medical education.

Gilherme Suarez-Kurtz, MD, Doct Med Nominated for Councilor

Guilherme Suarez-Kurtz (Brazil) graduated from the Faculty of Medicine, Universidade do Brasil and received his Doctor of Medicine degree from Universidade Federal do Rio de Janeiro. He completed postgraduate training at Faculté de Médecine de Paris, the University of Pennsylvania in Philadelphia, Columbia University in New York, and University College London.

Prof. Suarez-Kurtz developed his academic career at Universidade Federal do Rio de Janeiro, becoming a Full Professor of Basic and Clinical Pharmacology in 1984. In 1997, he moved to the Brazilian National Cancer Institute, as Head of the Research Division.

Prof. Suarez-Kurtz pioneered studies of pharmacogenomics in admixed populations, particularly Brazilians. He founded remains the coordinator of the Brazilian Pharmacogenomics Network (Refargen), which congregates 19 research groups in the country. He has published approximately 200 full papers and reviews in international journals, advised over 30 M.Sc. dissertations and Ph.D. theses, dozens of undergraduate students, and has produced several educational videos in pharmacology.

Prof. Suarez-Kurtz represented Brazil in the International Agency for Cancer Research (Lyon, 2000-2002), chaired the 2nd Latin American Congress of Pharmacogenomics and Personalized Medicine (Rio de Janeiro, 2012), and was

Gilherme Suarez-Kurtz, MD, Doct Med Nominated for 2018-2022 Councilor (continued)

the Editor of the book [Pharmacogenomics in Admixed Populations](#) (Landes Biosciences). He is a Member of the Editorial Boards of British Journal of Clinical Pharmacology, Pharmacogenomics and Frontiers in Pharmacology.

Prof. Suarez-Kurtz is a Senior Investigator of Brazilian National Research Council, a Full Member of the Brazilian Academy of Sciences, and is the Chair of the Pharmacogenetics and Pharmacogenomics Section of IUPHAR from July, 2014 through July, 2018.

David Webb, MD, PhD Nominated for 2018-2022 Councilor

David Webb (United Kingdom) was born, educated and trained in London, and gained his MB BS in 1977 (University of London), MD in 1990 (University of London) and DSc in 2000 (University of Edinburgh). He undertook research training in the MRC Blood Pressure Unit, Glasgow, and Department of Pharmacology and Clinical Pharmacology, St Georges, University of London. After a Senior Lectureship in Medicine at the University of Edinburgh, he was appointed as the Christison Professor of Therapeutics & Clinical Pharmacology in 1995. He has held positions as a physician and clinical pharmacologist/toxicologist in Edinburgh since 1990, and runs Edinburgh's Hypertension Excellence Centre.

Dr. Webb ran Edinburgh University's Department of Medicine (1997 – 2001), established and led its Centre for Cardiovascular Science (CVS) and Wellcome Trust-funded Cardiovascular Initiative (1998), and has directed Medical Research Council and Wellcome Trust funded Translational Medicine and Therapeutics Initiatives (2007 – 2015). He currently leads the Hypertension and Renal Theme of Edinburgh's CVS. He is a Fellow of the Academy of Medical Sciences, American Heart Association, British Pharmacological Society, Faculty of Pharmaceutical Physicians, Royal College of Physicians (Edinburgh and London) and Royal Society of Edinburgh.

Dr. Webb's main clinical and research interest is in hypertension, focusing on arterial stiffness, endothelial dysfunction and chronic kidney disease. His work on the hormone endothelin over a period of around 30 years has underpinned current clinical trials of endothelin antagonists in hypertension, diabetes and chronic kidney disease. He has published over 700 peer-reviewed papers on clinical pharmacology and cardiovascular disease (h-Index 100), and five books on cardiovascular topics. He is involved in teaching and training, mainly of postgraduate physicians and scientists (>30 PhDs to date).

Dr. Webb is immediate Past President of the BPS (2016 – 2017), having previously held a number of other roles, including Vice President Clinical and Vice President Meetings. He was awarded BPS's biennial Silver Medal for research in 1994, and the Lilly Prize and Gold Medal for contributions to clinical pharmacology in 2003. In addition to serving as Vice Chair, then Chair, of the IUPHAR Division of Clinical Pharmacology, he is future President of the IUPHAR World Congress of Basic & Clinical Pharmacology to be held in Glasgow in 2022, having been President of the European Society for Clinical Pharmacology & Therapeutics (EACPT) Congress in 2009.

Dr. Webb is a non-executive director of the Medicines and Healthcare products Regulatory Agency (MHRA), an Executive Agency of the UK Department of Health. MHRA also incorporates the National Institute for Biological Standards and Control (NIBSC), for which Dr. Webb chairs the Scientific Advisory Committee. In Scotland, he has chaired the Scottish Medicines Consortium (SMC: Scotland's equivalent of NICE), and been President of the Scottish Society of Physicians and Vice President of the Royal College of Physicians of Edinburgh.

In his spare time, he enjoys holidays with his wife, who is a paediatric endocrinologist, with a focus on rock climbing, ski touring, diving and biking – no beach holidays!

